Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Bought by Knights of Columbus Asset Advisors LLC

Knights of Columbus Asset Advisors LLC raised its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALOFree Report) by 16.7% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 93,293 shares of the biopharmaceutical company’s stock after purchasing an additional 13,352 shares during the period. Knights of Columbus Asset Advisors LLC owned about 0.07% of Halozyme Therapeutics worth $3,564,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of Halozyme Therapeutics by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 13,335,155 shares of the biopharmaceutical company’s stock valued at $527,273,000 after acquiring an additional 38,342 shares in the last quarter. Artisan Partners Limited Partnership raised its position in shares of Halozyme Therapeutics by 6.7% during the 2nd quarter. Artisan Partners Limited Partnership now owns 7,459,511 shares of the biopharmaceutical company’s stock valued at $269,065,000 after acquiring an additional 467,322 shares in the last quarter. Snyder Capital Management L P raised its position in shares of Halozyme Therapeutics by 0.7% during the 2nd quarter. Snyder Capital Management L P now owns 4,323,512 shares of the biopharmaceutical company’s stock valued at $155,949,000 after acquiring an additional 28,328 shares in the last quarter. Macquarie Group Ltd. raised its position in shares of Halozyme Therapeutics by 22.8% during the 1st quarter. Macquarie Group Ltd. now owns 3,200,481 shares of the biopharmaceutical company’s stock valued at $122,226,000 after acquiring an additional 595,220 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Halozyme Therapeutics by 3.8% during the 2nd quarter. Geode Capital Management LLC now owns 2,730,268 shares of the biopharmaceutical company’s stock valued at $98,481,000 after acquiring an additional 98,881 shares in the last quarter. 92.59% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $39.63, for a total value of $396,300.00. Following the completion of the transaction, the senior vice president now owns 151,911 shares of the company’s stock, valued at $6,020,232.93. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 2.40% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. Benchmark reissued a “buy” rating and set a $50.00 price target on shares of Halozyme Therapeutics in a research report on Friday, October 20th. StockNews.com raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research report on Monday, December 25th. Morgan Stanley dropped their target price on Halozyme Therapeutics from $61.00 to $59.00 and set an “overweight” rating on the stock in a research report on Tuesday, December 26th. Finally, HC Wainwright dropped their target price on Halozyme Therapeutics from $61.00 to $48.00 and set a “buy” rating on the stock in a research report on Thursday. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $51.36.

Get Our Latest Report on HALO

Halozyme Therapeutics Trading Down 0.9 %

NASDAQ:HALO opened at $36.04 on Thursday. Halozyme Therapeutics, Inc. has a 1 year low of $29.85 and a 1 year high of $53.71. The stock has a market cap of $4.76 billion, a price-to-earnings ratio of 19.17, a PEG ratio of 0.36 and a beta of 1.23. The business has a fifty day moving average of $38.10 and a 200-day moving average of $38.97. The company has a debt-to-equity ratio of 6.01, a quick ratio of 6.51 and a current ratio of 7.63.

Halozyme Therapeutics (NASDAQ:HALOGet Free Report) last released its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.02. Halozyme Therapeutics had a return on equity of 190.74% and a net margin of 32.52%. The company had revenue of $216.03 million during the quarter, compared to analysts’ expectations of $219.47 million. Equities analysts predict that Halozyme Therapeutics, Inc. will post 2.52 earnings per share for the current year.

Halozyme Therapeutics Profile

(Free Report)

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Featured Stories

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALOFree Report).

Institutional Ownership by Quarter for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.